摘要
目的:比较分析康复新液/薄芝糖肽联合抗结核方案治疗肺结核合并糖尿病患者的临床疗效及对免疫功能影响.方法:选择2019年1月~2020年12月在我院就诊治疗的肺结核合并糖尿病患者220例作为研究对象,根据随机数字表法将患者随机分为康复新液组和薄芝糖肽组,每组各110例.所有患者接受降糖和抗结核治疗,予异烟肼、利福平、吡嗪酰胺、乙胺丁醇抗结核治疗3个月.康复新液组采用康复新液联合治疗,薄芝糖肽组采用薄芝糖肽注射液治疗,共治疗3个月.比较两组患者临床疗效、T淋巴细胞亚群CD8^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平、痰结核菌阴转情况、症状缓解时间、生活质量综合评定问卷(GQOLI-74评分)、外周血白细胞介素2受体(sIL-2R)、γ-干扰素(IFN-γ)水平和不良反应发生情况.结果:两组患者总有效率比较差异不明显;治疗后2、3个月与治疗前比较,两组CD4^(+)和CD4^(+)/CD8^(+)水平都升高,且康复新液组高于薄芝糖肽组,CD8^(+)水平都降低,且康复新液组低于薄芝糖肽组;两组患者治疗2个月的痰结核菌阴转率差异无统计学意义,治疗3个月后康复新液组痰结核菌阴转率高于薄芝糖肽组,两组患者的平均症状缓解时间无明显差异,GQOLI-74评分在治疗前无明显差异,治疗后康复新液组高于薄芝糖肽组.两组患者治疗前、治疗2个月sIL-2R和IFN-γ水平比较无明显差异;治疗3个月康复新液组sIL-2R水平低于薄芝糖肽组,IFN-γ水平高于薄芝糖肽组.两组患者总不良反应发生率差异无统计学意义.结论:与薄芝糖肽相比,康复新液联合抗结核方案治疗肺结核合并糖尿病患者的临床疗效更高,改善免疫功能效果更优,生活质量更高,并且未出现严重不良反应.
Objective To compare and analyze the clinical efficacy of kangfuxin liquid/Bulgossypiin combined anti-tuberculosis regimen in the treatment of patients with pulmonary tuberculosis complicated with diabetes and its influence on immune function.Methods A total of 220 patients with pulmonary tuberculosis complicated with diabetes who were treated in our hospital from January 2019 to December 2020 were selected as the study subjects.According to the random number table method,the patients were randomly divided into kangfuxin liquid group and Chizhi glycopeptide group,with 110 cases in each group.All patients received hypoglycemic and anti-tuberculosis treatment,and were given isoniazid,rifampicin,pyrazinamide and ethambutol anti-tuberculosis treatment for 3 months.The kangfuxin liquid group was treated with kangfuxin liquid combined treatment,and the chizhi glucopeptide group was treated with Chizhi glucopeptide injection for 3 months.Clinical efficacy,CD8^(+),CD4^(+),CD4^(+)/CD8^(+)levels of T lymphocyte subsets,negative transformation of sputum tuberculosis,symptom relief time,comprehensive assessment questionnaire(GQOLI-74 score)and peripheral blood interleukin 2 were compared between 2 groups The levels of sil-2R and IFN-y and the incidence of adverse reactions.Results There was no significant difference in the total effective rate between the two groups.Two and three months after treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)were increased in both groups compared with before treatment,and the levels of CD8^(+)were decreased in kangfuxin liquid group,and the levels of CD4^(+)and CD4^(+)/CD8^(+)in kangfuxin liquid group were lower than that in kangfuxin liquid group.There was no significant difference in the negative conversion rate of TB in 2 months of treatment between the two groups,and the negative conversion rate of TB in kangfuxin solution group was higher than that in gqoli-74 group after 3 months of treatment.There was no significant difference in the average symptom relief time between the two groups,
作者
汪胤
唐硕润
Wang Yin;Tang Shuo-run(Hunan Chest Hospital,Changsha 410005,China)
出处
《湖南师范大学学报（医学版）》
2022年第2期77-81,共5页
Journal of Hunan Normal University(Medical Sciences)
关键词
康复新液
薄芝糖肽
肺结核
糖尿病
kangfuxin liquid
thin zhi glycopeptide
pulmonary tuberculosis
diabetes mellitus
